A PHASE 1, OPEN-LABEL, MAXIMAL USE TRIAL TO ASSESS THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PP405 TOPICAL GEL 0.05% IN ADULT PARTICIPANTS WITH ANDROGENETIC ALOPECIA

Registry ID

PP405-002

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

PELAGE PHARMACEUTICALS, INC.

Start date

2025-12-17

Completion date

2026-04-22

Last update

2025-12-16

Conditions

• ANDROGENIC ALOPECIA

Related clinical trials

• A PHASE III, PARALLEL DESIGN, TRIPLE-BLIND, RANDOMIZED, MULTICENTER CLINICAL TRIAL TO EVALUATE SAFETY & EFFICACY OF TH07 TOPICAL TREATMENT IN MALE PATIENTS WITH ANDROGENIC ALOPECIA

View on source registry